NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Th...(escription of historical facts are forwa...)

Date:5/8/2008

escription of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties, relative to the proposed acquisition, include, but are not limited to: the risk that the parties may not consummate the transaction in the expected timeframe or that intervening factors may cause the parties to alter the terms (financial or otherwise) of the transaction; the risk that NuVasive may not be able to achieve expected synergies and strategic benefits from Osteocel or the acquired technology; the risk that NuVasive will not be able to successfully integrate the acquired operations; the risk that revenues or profits following the transaction will be lower than expected; the risk that business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) is greater than expected following the transaction; and the risk that NuVasive will not be able to acquire or produce a sufficient supply of product following the transaction. Additionally, other factors that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasi
'/>"/>

SOURCE NuVasive, Inc. Copyright©2008 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
2. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
3. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
4. NuVasive to Host Investor Reception on September 11, 2007
5. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
6. Quintiles Signs Agreement to Acquire Eidetics
7. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
8. Assay Designs(TM) Announces Collaboration with Medical University of South Carolina (MUSC)
9. Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation
10. DelSite Signs Technology Evaluation Agreement With Global Pharmaceutical Company for GelSite(R) Polymer
11. Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.